Market by Therapeutics, Diagnostics, and Country Outlook | Forecast 2022-2028
The Alzheimer’s disease
therapeutics and diagnostics market in North America is anticipated to rise
with a CAGR of 6.82% over the estimated period from 2022 to 2028.
Report scope can be customized per your requirements. Request For Customization
The countries evaluated in this market are:
•
The United States
•
Canada
The market for
Alzheimer’s disease therapeutics and diagnostics is predicted to expand in
North America as a result of the possibility of new medicines receiving
regulatory approval as well as the anticipated increase in sales of Namenda XR,
the extended-release version of the drug Namenda. Government institutions are
also focusing on innovation and developing diagnostic & therapeutic tools for
Alzheimer’s disease, which is accelerating the studied market’s expansion in this
region.
The Alzheimer Society
of Canada estimates that, each year, nearly 25,000 new cases of dementia are
diagnosed in Canada. The number is anticipated to climb to 937,000 by 2031,
with an increase of 66%. The majority of dementia cases—roughly 64% of the
cases—are caused by Alzheimer’s disease. Additionally, it has been noted that
while memantine is approved for use in people with moderate or severe AD,
donepezil, rivastigmine, and galantamine are only approved for use in those
with mild or moderate AD.
Most of the significant
AD medication trials have been sponsored by pharmaceutical companies.
Additionally, advocacy groups like the Alzheimer’s Society of Canada are
working to improve drug coverage. The National Clinical Trials Registry (NCT)
estimates that there are now roughly 29 active Alzheimer’s disease clinical
trials in various stages of development in Canada. Thus, as a result of the above-mentioned
factors, the Alzheimer’s disease therapeutics and diagnostics market in the
country is anticipated to witness substantial growth over the forecasting
period.
A lumbar puncture test
involves the use of biomarkers for Alzheimer’s disease diagnosis. This test is
also often referred to as a spinal tap, which is a minimally invasive procedure
that uses cerebrospinal fluid (CSF) for diagnostic testing. A needle is inserted
in the spinal canal during a lumbar puncture test to diagnose illnesses of the
central nervous system, which includes the brain and spine. This procedure is
used to diagnose Alzheimer’s at the beginning stages of the disease. Due to
declining usage over time and the introduction of blood tests into the market,
it is projected that the growth of the lumbar test segment will slow down over
the forecasted period.
The
report assesses the market based on therapeutics and diagnostics. The
diagnostics segment consists of lumbar puncture test, blood test, computed
tomography, electroencephalography, magnetic resonance imaging, positron
emission tomography, and other diagnostics.
The
acclaimed players in the Alzheimer’s disease therapeutics and diagnostics
market include Cognoptix Inc, Eli Lilly & Company, Biogen Inc, Allergan Plc
(acquired by Abbvie), Pfizer Inc, Eisai Co Ltd, Johnson and Johnson, and Sun
Pharmaceuticals Industries Ltd.
Amarantus BioScience
Holdings Inc is a pharmaceutical company engaged in developing therapeutic and
diagnostic products for neurology, ophthalmology, and psychiatric &
regenerative medicine. The diagnostics division of the business concentrates on
developing & commercializing neurologic diagnostic products. The company
offers a distinctive range of diagnostics to detect the early onset of
conditions like Alzheimer’s, multiple sclerosis, and other diseases. “The
LymPro Test” is a blood-based assay developed by the company for mild to
moderate AD diagnosis. Amarantus BioScience is headquartered in California, the
United States.
Key deliverables of the report:
·
Market
CAGR during the forecasting years 2022-2028
·
Detailed
data highlighting key insights, industry components, and market strategies
·
Comprehensive
information and estimation of the Alzheimer’s disease therapeutics and diagnostics
market revenue growth in North America and its influence on the parent market
·
In-depth
study of forthcoming trends in consumer behavioral patterns
·
A
meticulous analysis of the competitive landscape, vendor scorecard, and
Porter’s Five Forces Analysis Model
·
A
wide-ranging study of factors that will challenge the North America Alzheimer’s
disease therapeutics and diagnostics market’s growth during the upcoming years
Want
to get specific insights? Our team of analysts can customize this report based
on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TIMELINE
OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY
INSIGHTS
2.3.1. USAGE
OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D
INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND
FOR PERSONALIZED MEDICINES
2.4. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S
FIVE FORCES ANALYSIS
2.6. MARKET
ATTRACTIVENESS MATRIX
2.7. VENDOR
SCORECARD
2.8. INDUSTRY
COMPONENTS
2.8.1. RESEARCH
& DEVELOPMENT (R & D)
2.8.2. RAW
MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY
IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& AGREEMENTS
2.10.4. INVESTMENTS
& EXPANSIONS
2.11. MARKET
DRIVERS
2.11.1. PREVALENCE
OF ALZHEIMER’S DISEASE
2.11.2. RISE
IN THE ELDERLY POPULATION
2.12. MARKET
CHALLENGES
2.12.1. FAILURE
OF LATE-STAGE DRUGS
2.12.2. STRINGENT
GOVERNMENT REGULATIONS
2.13. MARKET
OPPORTUNITIES
2.13.1. EMERGENCE
OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING
NUMBER OF PIPELINE DRUGS
3. NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY
THERAPEUTICS
3.1. BY
DRUG TYPE
3.1.1. MARKETED
DRUGS
3.1.2. PIPELINE
DRUGS
3.2. BY
DISEASE STAGE
3.2.1. LATE
STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL
STAGE
3.3. BY
GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY
DIAGNOSTICS
4.1. LUMBAR
PUNCTURE TEST
4.2. POSITRON
EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC
RESONANCE IMAGING
4.5. COMPUTED
TOMOGRAPHY
4.6. BLOOD
TEST
4.7. OTHER
DIAGNOSTICS
5. NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – COUNTRY
OUTLOOK
5.1. UNITED
STATES
5.2. CANADA
6. COMPETITIVE
LANDSCAPE
6.1. BAXTER
INTERNATIONAL INC
6.2. F.
HOFFMANN-LA ROCHE AG
6.3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS
AG
6.5. PFIZER
INC
6.6. SIEMENS
HEALTHINEERS AG
6.7. AMARANTUS
BIOSCIENCE HOLDINGS INC
6.8. EISAI
CO LTD
6.9. ELI
LILLY & COMPANY
6.10. LUPIN
LIMITED
6.11. MERCK
AND CO
6.12. BIOGEN
INC
6.13. COGNOPTIX
INC
6.14. GE
HEALTHCARE
6.15. JOHNSON
AND JOHNSON
6.16. SUN
PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS
CADILA
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
TABLE 2: MARKET
ATTRACTIVENESS MATRIX
TABLE 3: VENDOR
SCORECARD
TABLE 4: KEY STRATEGIC
DEVELOPMENTS
TABLE 5: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 6: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 7: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 8: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 9: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
TABLE 10: NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE
FORCES ANALYSIS
FIGURE 2: KEY IMPACT
ANALYSIS
FIGURE 3: TIMELINE OF
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE 4: INDUSTRY
COMPONENTS
FIGURE 5: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021
& 2028 (IN %)
FIGURE 6: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)
FIGURE 7: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 8: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 9: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN
%)
FIGURE 10: NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD,
2022-2028 (IN $ MILLION)
FIGURE 11: NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO
MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE 12: NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028
(IN $ MILLION)
FIGURE 13: NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021
& 2028 (IN %)
FIGURE 14: NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $
MILLION)
FIGURE 15: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)
FIGURE 16: NORTH
AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
DIAGNOSTICS, 2021 & 2028 (IN %)
FIGURE 17: NORTH
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST,
2022-2028 (IN $ MILLION)
FIGURE 18: NORTH
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION
TOMOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE 19: NORTH
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 20: NORTH
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING,
2022-2028 (IN $ MILLION)
FIGURE 21: NORTH
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028
(IN $ MILLION)
FIGURE 22: NORTH
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $
MILLION)
FIGURE 23: NORTH
AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028
(IN $ MILLION)
FIGURE 24: NORTH AMERICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
& 2028 (IN %)
FIGURE 25: UNITED
STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 26: CANADA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)